Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antiviral Activity of Remdesivir and Obeldesivir Against SARS-CoV-2 Omicron Subvariants That Were Circulating from September 2023 Through June 2025.

Viruses - 18 Feb 2026

Rodriguez Lauren, Li Jiani, Han Dong, Peinovich Nadine, Martinez Clarissa, Ho Pui Yan, Zamora J Lizbeth Reyes, Martin Ross, Bilello John P, Perry Jason K, Hedskog Charlotte

Abstract excerpt

With the ongoing emergence of SARS-CoV-2 variants, continued surveillance of antiviral susceptibility remains critical for detecting resistance that could compromise treatment efficacy. This study evaluated the activity of 2 SARS-CoV-2 RNA-dependent RNA polymerase (Nsp12) inhibitors against emerging Omicron variants: remdesivir (RDV), an approved antiviral for the treatment of COVID-19, and obeldesivir (ODV), an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine
Share to Adenosine Monophosphate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alanine

Share to Chlorocebus aethiops

Share to COVID-19

Share to COVID-19 Drug Treatment

Share to SARS-CoV-2

Share to Vero Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 41754598
DOI: 10.3390/v18020255
PMCID: PMC12944983

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antiviral Activity of Remdesivir and Obeldesivir Against SARS-CoV-2 Omicron Subvariants That Were Circulating from September 2023 Through June 2025.PMID 41754598Read ↗

Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variantsSemantic proximity Read ↗

Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron VariantsSemantic proximity Read ↗

Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariantsSemantic proximity Read ↗

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 VariantsSemantic proximity Read ↗

Clinical evidence of the effectiveness of remdesivir in COVID-19 during periods dominated by Delta and Omicron SARS-CoV-2 variants.Semantic proximity Read ↗

Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent <i>in vitro</i> activity against the SARS-CoV-2 Omicron variantSemantic proximity Read ↗

SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participantsSemantic proximity Read ↗

Efficacy of antiviral drugs against the omicron variant of SARS-CoV-2Semantic proximity Read ↗

SARS-CoV-2 Resistance to Small Molecule InhibitorsSemantic proximity Read ↗

SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug ResistanceSemantic proximity Read ↗

Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variantsSemantic proximity Read ↗

Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.